About UCSF Search UCSF UCSF Medical Center

Jeffrey M. Venstrom, MD


Assistant Professor, Department of Medicine (Hematology/Oncology), UCSF
Krishnamurthi Endowed Chair in Hematologic Malignancies, UCSF

Additional Websites


Vanderbilt University, Vanderbilt School of Medicine, BS, 1995-1999, Neuroscience
Vanderbilt University, Vanderbilt School of Medicine, MD, 1999-2004, Medicine
National Institutes of Health, NIDDK, 2002-2003, Clinical Research
Johns Hopkins Hospital, Residency, 2004-2006, Internal Medicine
Memorial Sloan-Kettering Cancer Center, Fellowship, 2006-2010, Hematology/Oncology

Professional Experience

  • 2002-2003
    Research Fellow, National Institutes of Health, NIDDK, NIH Intramural Clinical Research Training Program
  • 2004-2006
    Resident, Internal Medicine, Johns Hopkins Hospital. American Board of Internal Medicine Research Pathway - Internal Medicine Training
  • 2006-2010
    Fellow, Medical Oncology and Hematology, Memorial Sloan-Kettering Cancer Center, American Board of Internal Medicine Research Pathway - Clinical Subspecialty and Research Training
  • 2010-present
    Assistant Professor of Clinical Medicine, University of California, San Francisco

Honors & Awards

  • 1998
    Phi Beta Kappa
  • 1999
    Graduation with Honors, summa cum laude
  • 2003
    Alpha Omega Alpha
  • 2002
    Medical Student Fellow, NIH Intramural Clinical Research Training Program/Curriculum
  • 2008
    Merit Award, American Society of Clinical Oncology
  • 2008
    Cornell Clinical and Translational Science Center, Clinical Research Scholar Award

Selected Publications

  1. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
    View on PubMed
  2. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012 Aug 30; 367(9):805-16.
    View on PubMed
  3. Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012 Sep 4; 122(9):3260-70.
    View on PubMed
  4. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu KC. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010 Apr 15; 115(15):3162-5.
    View on PubMed
  5. Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009 Dec 1; 15(23):7330-4.
    View on PubMed
  6. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood. 2009 Apr 16; 113(16):3875-84.
    View on PubMed
  7. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA. 2003 Dec 3; 290(21):2817-23.
    View on PubMed
  8. Hirshberg B, Rother KI, Digon III BJ, Venstrom J, Harlan DM. State of the art: islet transplantation for the cure of type 1 diabetes mellitus. Rev Endocr Metab Disord. 2003 Dec; 4(4):381-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI